BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity (Silver Spring) 2021;29:1950-60. [PMID: 34553836 DOI: 10.1002/oby.23263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Park H, Yoon EL, Kim M, Cho S, Kim JH, Jun DW, Nah EH. Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea. J Clin Med 2022;11:1474. [PMID: 35329799 DOI: 10.3390/jcm11061474] [Reference Citation Analysis]
2 Barb D, Cusi K. Response to: "Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?". Obesity (Silver Spring) 2022. [PMID: 35394120 DOI: 10.1002/oby.23422] [Reference Citation Analysis]
3 Li G, Li X, Yang L, Wang S, Dai Y, Fekry B, Veillon L, Tan L, Berdeaux R, Eckel-Mahan K, Lorenzi PL, Zhao Z, Lehner R, Sun K. Adipose tissue-specific ablation of Ces1d causes metabolic dysregulation in mice. Life Sci Alliance 2022;5:e202101209. [PMID: 35459739 DOI: 10.26508/lsa.202101209] [Reference Citation Analysis]
4 Cusi K. A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now. J Clin Endocrinol Metab 2022;107:e3076-7. [PMID: 35333917 DOI: 10.1210/clinem/dgac186] [Reference Citation Analysis]
5 Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2021;161:1657-69. [PMID: 34602251 DOI: 10.1053/j.gastro.2021.07.049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Scarlat G, Dona B, Cârstea M, Stoian M. Insights into Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Internal Medicine 2022;19:61-77. [DOI: 10.2478/inmed-2022-0198] [Reference Citation Analysis]
7 Li L, Huang Q, Yang L, Zhang R, Gao L, Han X, Ji L, Zou X. The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004. Nutrients 2022;14:1224. [PMID: 35334881 DOI: 10.3390/nu14061224] [Reference Citation Analysis]
8 Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022;28:528-62. [PMID: 35569886 DOI: 10.1016/j.eprac.2022.03.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
9 Zhang K, Yuan Y, Dawa Z, Liu F, Yao Y, Wang M, Zhu C, Lin C. Integrating metabolomics and network pharmacology to reveal the mechanisms of Delphinium brunonianum extract against nonalcoholic steatohepatitis. J Ethnopharmacol 2022;293:115268. [PMID: 35398502 DOI: 10.1016/j.jep.2022.115268] [Reference Citation Analysis]
10 Williams DM, Krishnamoorthy SV, Ch’ng CL, Stephens JW, Min T. Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored? Obesity. [DOI: 10.1002/oby.23423] [Reference Citation Analysis]
11 Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. The Lancet Diabetes & Endocrinology 2022;10:284-96. [DOI: 10.1016/s2213-8587(22)00003-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]